HOME >> BIOLOGY >> NEWS
Brandeis and Brigham and Women's Hospital license technology for Gaucher's to Amicus Therapeutics

Waltham, MABrandeis University and Brigham and Women's Hospital today agreed to grant a license option to Amicus Therapeutics for a jointly-developed novel pharmaceutical technology that could be instrumental in finding new treatments for Gaucher Disease. Biochemists Raquel Lieberman, Gregory Petsko and Dagmar Ringe, each affiliated with both Brandeis and Brigham and Women's, invented a patentable technology related to the structure of acid beta-glucosidase, also known as GCase, and methods for identifying therapeutic agents. In collaboration with scientists at Amicus Therapeutics, the inventors discovered that GCase, the protein that is mutated in Gaucher Disease, undergoes a structural change near its active site upon binding to a small molecule that is in clinical trials for the treatment of the disease.

One emerging type of treatment for genetic diseases such as Gaucher Disease involves the use of small molecules known as pharmacological chaperones, which are proposed to help mutated, less stable proteins perform their normal function in the cells of patients with the disease. The identification of appropriate pharmacological chaperones and understanding how they work in the body are aided by knowing the structure of the target protein under different conditions and when bound to the small molecule.

Cranbury, New Jersey-based Amicus Therapeutics, which specializes in the discovery and development of pharmacological chaperones, will use this structure of GCase to look for additional small molecules that can keep the protein properly folded and stabilized.

"This work helps explain the way pharmacological chaperones work to stabilize proteins that are rendered less stable by genetic mutations in diseases such as Gaucher, Anderson-Fabry, and other genetic disorders," explained Petsko, the Gyula and Katica Tauber Professor of Biochemistry and Chemistry, Brandeis University and Adjunct Professor, Department of Neurology and Center
'"/>

Contact: Laura Gardner
gardner@brandeis.edu
781-736-4204
Brandeis University
22-Feb-2007


Page: 1 2

Related biology news :

1. New Brandeis research sheds light on memory by erasing it
2. National Academy of Sciences elects 2 Brandeis University scientists to membership
3. Biogen Idec acquires Brandeis spin-out
4. HHMI awards Brandeis professor $1 million to draw minorities into science
5. Carl and Ruth Shapiro family donates $25 million for new science center at Brandeis University
6. American Physical Society honors outstanding achievements of two Brandeis scientists
7. Brandeis biologist wins top award in neuroscience
8. Brandeis wins $1 million grant to train scientists in solving 21-century biomedical problems
9. AAAS and Brandeis University announce 2005 Fellows
10. Brandeis leads collaborative team in researching chemical processes in brain
11. MIT, Brigham: Nanoparticles armed to combat cancer

Post Your Comments:
(Date:7/31/2014)... Census Bureau, Latinos are the largest minority group in ... Approximately one-third of Latinos are obese and are 1.2 ... Whites. , NYU College of Nursing student researcher ... identify the factors that contribute to this problem by ... on food patterns in Latina women recently published in ...
(Date:7/31/2014)... of the roughly 156,000 gas stations across the ... parts of underground gas storage tankscorrosion that could ... a source of drinking water. In recent years, ... rapidly corroding gas storage tank components such as ... use of gasoline-ethanol blends and the presence of ...
(Date:7/31/2014)... An experimental vaccine protected 100 percent of animal models ... difficile , which causes an intestinal disease that kills ... of print in Infection and Immunity . ... and non-human primates against the purified toxins produced by ... orogastric spore infection, a laboratory model that mimics the ...
Breaking Biology News(10 mins):NYU research looks to combat US Latina immigrant obesity 2NIST corrosion lab tests suggest need for underground gas tank retrofits 2C. difficile vaccine proves safe, 100 percent effective in animal models 2
(Date:7/31/2014)... The global market for molecular diagnostics is expected to ... new study by Grand View Research, Inc. Growing demand ... of advanced cancer diagnostic technologies are expected to be ... years. Moreover, the growing global base of geriatric population ... triggering lifestyle habits such as smoking and excessive alcohol ...
(Date:7/31/2014)... 31, 2014   BioLife Solutions , Inc. (NASDAQ: ... marketer of proprietary clinical grade hypothermic storage ... thermal shipping products for cells and tissues, today ... results will be released on Thursday, August 7, 2014, ... and live webcast at 4:30 p.m. ET that afternoon. ...
(Date:7/31/2014)... July 31, 2014 Boston’s Adult Stem ... flush with innovative adult stem cell biotechnologies. Currently ... and has three additional patent applications currently under examination ... patented inventions address two of the most vexing problems ... Adult stem cells are difficult to identify; and ...
(Date:7/30/2014)... , July 30, 2014  Regeneron Pharmaceuticals, Inc. ... today announced that the Companies intend to use a ... priority review voucher in connection with the Biologics License ... entitles the holder to designate a BLA for priority ... the filing date instead of the standard 10-month review. ...
Breaking Biology Technology:Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 2Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 3Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 4Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 5BioLife Solutions to Report Financial Results for Second Quarter 2014 and Provide Business Update on August 7, 2014 2The Adult Stem Cell Technology Center, LLC Launches A Marketing Campaign To License Adult Stem Cell Biotechnologies 2The Adult Stem Cell Technology Center, LLC Launches A Marketing Campaign To License Adult Stem Cell Biotechnologies 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 4Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 5Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 6
Cached News: